Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (220)	7/11/1998 9:28:00 PM
From: Marc Kahn	Read Replies (1) \| Respond to of 534

Jim: Looks like the analyst is saying -.04 for FY 99 (this year) and .31 for FY 2000 (next year). This is certainly more plausible than .31 for FY99, but I'd sure like to know the basis for his assumptions. Maybe he's reading this board. If so, come forward and tell us what you know (or think). Marc

To: James Strauss who wrote (220)	7/20/1998 9:34:00 PM
From: Marc Kahn	Read Replies (2) \| Respond to of 534

Jim, 10 days ago, we were discussing an unknown analyst's earnings estimate and wondering about his assumptions. It turns out that I have been sitting on his report for more than a year, and forgot all about it. His name is Frank Lyles, MD and he works for a research company called Preferred Technology, Inc., of San Francisco (415-781-4572). The report that I have is dated 2/13/97, and indeed projects EPS of .31 for FY2000. This is based on product sales of $31.35M. He rates BJCT as a Strong Buy. The research report is 8 pages long, and very informative. I especially found the section on DNA vaccines and genetic therapies to be interesting, in that it validates what I have gathered from other sources. Here's what he says: "Bioject's technology gives it a distinct advantage with DNA vaccines and genetic therapies. These treatments require that injected DNA make physical contact with each cell. Bioject's injection pattern disperses into the tissue which allows the DNA access to all the cells in the dispersion pattern; whereas a needle creates a sac of fluid and only the cells that directly surround the sac will be exposed. Bioject's jet injection pattern effectively surrounds each cell and leads to higher DNA transfection rates and improved efficacy. Published data demonstrates that Bioject's device is superior to needles, giving over four fold higher expression of the target protein. Genetic vaccines received much attention in the past year as demonstrated by a noted industry leader, Pasteur Merrieux Connaught, expanding its pipeline of "naked DNA" vaccines to six. DNA vaccines have been noted in the recent scientific literature to give better protection and to be simpler to manufacture. Bioject is in prime position to capitalize on this significant opportunity."